Skip to NavigationSkip to content

FDA approves Beximco's generic version of MSD's allergy drug Periactin

Published on 25/04/19 at 12:00pm

Bangladesh-based Beximco Pharma is celebrating following the decision from the FDA to approve its generic version of MSD’s antihistamine therapy Periactin (Cyproheptadine).

The 4mg generic tablet formulation is approved in the same indications as its reference product, including the treatment of allergy symptoms such as hives, sneezing, and itchy or watery eyes or nose.

Beximco said that the total market in the US for the mediciation was around $16 million in 2018.

Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, commented: “Cyproheptadine is our seventh product approved for the US market, and with our recent acquisition of eight ANDAs from Sandoz, our US portfolio now stands at 15 products. This approval gives us further confidence that our strategic focus and growing pipeline will strengthen our presence in the world’s largest pharma market.”

Beximco was the first Bangladeshi pharma firm to export medicines to the US in August 2016 after its oral solid dosage facility was approved by the FDA in June 2015.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches